Management of Acute and Chronic Kidney Disease

Medication Management

• The American Society of Nephrology recommends that nephrotoxic medications should be avoided whenever possible during acute kidney disease, with special attention to avoiding multiple nephrotoxic medications simultaneously 1, 2
• When nephrotoxins are essential for treatment, efforts should be made to mitigate their nephrotoxic effects through careful dosing and monitoring, as suggested by the National Kidney Foundation 1, 3
• ACE inhibitors and ARBs often need to be temporarily discontinued during acute kidney disease episodes, with reintroduction considered only when GFR has stabilized and volume status is optimized, according to the American College of Cardiology 2, 3
• Drug selection should be guided by the functional phase, trajectory, and stage of acute kidney disease, considering factors such as renal versus non-renal excretion, as recommended by the European Renal Association 4
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that medication regimens in chronic kidney disease focus on long-term kidney protection and management of complications 7
• ACE inhibitors and ARBs are often beneficial for long-term kidney protection in chronic kidney disease, unlike their potential risks in acute kidney disease, as stated by the American Heart Association 2, 3
• Dose adjustments for renally eliminated drugs are required based on stable GFR measurements rather than fluctuating values seen in acute kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases 8, 5

Diagnostic Approach

• Rapid assessment of potential causes is essential in acute kidney disease, including recent exposure to nephrotoxins, volume status, and urinary tract obstruction, as recommended by the American Society of Nephrology 1, 9
• Medication histories should include prescribed drugs, over-the-counter medications, herbal supplements, and recreational substances that may contribute to acute kidney disease, according to the National Kidney Foundation 8, 5
• Kidney ultrasound after correction of hypovolemia is important to exclude urinary tract obstruction, as suggested by the European Renal Association 8, 5
• In cases of nonresolving acute kidney injury, rapidly progressive acute kidney disease, or acute kidney disease with significant urinary abnormalities, kidney biopsy may provide valuable diagnostic and prognostic information, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 8, 5
• The diagnostic approach for chronic kidney disease focuses on determining underlying etiology and assessing for complications, as recommended by the American College of Cardiology 7
• Regular monitoring of eGFR and albuminuria to track disease progression is essential in chronic kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases 8, 5

Follow-up Care

• Patients with acute kidney disease require close monitoring during the recovery phase, with follow-up of kidney function within days to weeks, as suggested by the American Society of Nephrology 1, 8
• Post-acute kidney disease care should include documentation of the acute kidney disease episode in medical records, education about acute kidney disease and its consequences, medication reconciliation, instructions on avoiding nephrotoxins, and follow-up of eGFR and albuminuria at least 3 months after hospital discharge, according to the National Kidney Foundation 5, 3, 1, 8, 5
• Nephrology follow-up during the acute kidney disease period is associated with lower mortality, fewer cardiovascular events, and reduced sepsis risk, as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 8, 5
• Regular long-term monitoring with less frequent intervals (typically every 3-12 months depending on stage) is recommended for chronic kidney disease, according to the American College of Cardiology 7
• Focus on slowing progression and managing complications is essential in chronic kidney disease, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 7

Common Pitfalls and Caveats

• Failing to recognize the transition from acute kidney disease to chronic kidney disease can lead to missed opportunities for intervention, as stated by the American Society of Nephrology 1, 8
• Inappropriate reintroduction of ACE inhibitors/ARBs too early during acute kidney disease recovery may worsen kidney function, according to the American College of Cardiology 2, 3
• Overlooking the importance of nephrology follow-up after acute kidney disease episodes significantly increases mortality risk, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 8, 5
• Underestimating the risk of drug-drug interactions in patients with kidney disease, particularly when multiple nephrotoxic medications are used simultaneously, is a common pitfall, according to the National Kidney Foundation 1, 2
• Neglecting to adjust medication dosages appropriately as kidney function changes during recovery from acute kidney disease can lead to adverse outcomes, as stated by the European Renal Association 4, 6
• Failing to provide adequate patient education about avoiding nephrotoxins (including NSAIDs and certain herbal supplements) after an acute kidney disease episode can increase the risk of future kidney injury, according to the National Institute of Diabetes and Digestive and Kidney Diseases 8, 5